Both GPX4 and system xc− are pharmacological targets of synthetic ferroptosis-inducing agents, with RSL3 and erastin having been major hits in screens for compounds toxic to otherwise highly treatment resistant RAS-mutated cancer cells [4, 5]. The gene discussed is GPX4; the disease is cancer.